Korea Suspends J&J Subsidiary Production Of 4 OTCs
This article was originally published in The Tan Sheet
Executive Summary
The Ministry of Food and Drug Safety orders a halt to manufacturing of five products after an investigation of GMP deviations at J&J’s Korean unit. Production of each of the products will be halted between one and five months.
You may also be interested in...
McNeil Remediation Stretches Out, Dragging On J&J Consumer Sales
The latest delay in Johnson & Johnson’s remediation of its McNeil OTC manufacturing pushes back FDA’s review of the Fort Washington, Pa., facility to “late 2013.” The firm’s Q1 results saw the worldwide consumer business fall 2.4% to $3.60 billion, including negative currency exchange effects.
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.